NCT05771012View on ClinicalTrials.gov

Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

October 1, 2022

Study Completion Date

December 1, 2022

Conditions

Management of Punctal Stenosis

Interventions

DRUG

0.05% cyclosporin (Restasis®, Allergan Inc)

study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)

DEVICE

mini-monoka stent

insertion of mini-monoka stent in the lower punctum in management of grade 1 and 2 acqquired punctal stenosis (group B)

Trial Locations (1)

13001

Farwanyia Hospital, Al Farwānīyah

All Listed Sponsors

lead

Farwaniya Hospital

OTHER_GOV

NCT05771012 - Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study. | Biotech Hunter | Biotech Hunter